Clearside Biomedical Shares Surge on Promising Clinical Data
Published on 09/26/2025 at 03:00 | Redaktion boerse-global.de
Clearside Biomedical’s stock experienced significant after-hours trading activity, climbing 6.82% to reach $4.23 per share. This upward movement provided a stark contrast to the regular trading session, during which the share price had declined by 9.79%. The catalyst for this positive reversal was the presentation of encouraging subgroup analyses from the Phase 2b ODYSSEY trial for the company’s wet age-related macular degeneration (AMD) treatment, CLS-AX, at the EURETINA congress.
Beyond the clinical developments, Clearside is undergoing a substantial corporate transformation. Since July 2025, the company, with guidance from investment bank Piper Sandler, has been evaluating a range of strategic alternatives. These options include potential asset sales, partnerships, or an outright sale of the company. This strategic review coincides with other significant corporate actions:
- A... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
